BioCryst Pharma (BCRX) Misses Q1 EPS by 8c

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.82 million versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c